Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367390 | 0.90 | L3MBTL1 (0.38) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL16367345 | 0.85 | L3MBTL1 (0.38) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL16367306 | 0.84 | L3MBTL1 (0.40) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL16367346 | 0.84 | L3MBTL1 (0.37) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL5536554 | 0.81 | PKM (0.42) | ALDH1A1MAPTHTTPKMUSP2 | |
| SCHEMBL5536543 | 0.81 | PKM (0.42) | ALDH1A1MAPTHTTPKMUSP2 | |
| SCHEMBL11867519 | 0.81 | PKM (0.41) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL15607849 | 0.77 | TAAR1 (0.56) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL15557382 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MAPTHTTL3MBTL1PKM | |
| SCHEMBL15607876 | 0.76 | ALDH1A1 (0.37) | ALDH1A1MAPTHTTUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | ALDH1A1 140/4885MAPT 3982/4885HTT 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.